Axogen, Inc. · NASDAQ:AXGN
Axogen — Investor Presentation (September 2026)
16 slides from Axogen's investor presentation, Sep 10, 2026
Slide 1: Making Nerve Repair an Expected Standard of Care: Company Overview
Making Nerve Repair an Expected Standard of Care Company Overview September 2026 CONFIDENTIAL
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995, which are statements that are not historical facts and relate to future conditions, events, or results. These statements are based on management's cu
Slide 3: Offering Summary
Offering Summary CONFIDENTIAL September 2026 2 Issuer Axogen, Inc. Ticker AXGN (NASDAQ) Base Offering Size $200,000,000 (common stock) Option to Purchase Additional Shares $30,000,000 (up to 15% of base deal, 100% primary) Use of Proceeds Acquisition of BioCircuit Technologies and general corporate
Slide 4: Our Mission
To restore health and improve quality of life by making restoration of peripheral nerve function an expected standard of care. Our Mission 3 CONFIDENTIAL
Slide 5: Large and Underserved Potential: $5.6B U.S. Nerve Care Opportunity
Large and Underserved Potential $5.6B U.S. Nerve Care Opportunity More than 1.5 million peripheral nerve injuries a year in the U.S. require treatment in Axogen focus markets1,2,3,7 Extremities Market Every year patients suffer from 700,000 traumatic nerve injuries and more than 370,000 chronic nerv
Slide 6: The Axogen Nerve Repair Algorithm
The Axogen Nerve Repair Algorithm Connection Protection Termination 5 CONFIDENTIAL
Slide 7: Accelerating Topline Drives Operational Leverage
Accelerating Topline Drives Operational Leverage Accelerating Revenue Growth Expanding EBITDA 2022 2023 2024 2025 $138.6 $159.0 $187.3 $225.2 ($25.6) ($15.5) $3.9 ($2.2) ($9.3) ($1.1) $19.8 $27.9 ($30.0) ($20.0) ($10.0) $0.0 $10.0 $20.0 $30.0 $40.0 EBITDA Adj. EBITDA* 2022 2023 2024 2025 *Excludes n
Slide 8: 2025-2028 Strategic Plan Priorities
2025-2028 Strategic Plan Priorities Strong momentum and execution of strategic plan priorities. Growth CAGR 15 - 20% Markets Elective and planned procedure focus Prostate market development Commercial Expansion Commercial infrastructure and salesforce expansion Commercial Excellence Continuous busin
Slide 9: BioCircuit Technologies At-a-Glance
BioCircuit Technologies At-a-Glance ~$24MM Run-Rate Revenue (Q2 2026 Annualized) KEY STATISTICS Commercializes NerveTape, the first FDA-cleared device for sutureless nerve repair Cost-efficient GTM model Strong visibility across surgeon networks Traction across markets and specialties ✓ ✓ ✓ ✓ 14,000
Slide 10: Challenges with Suture-Based Nerve Repair
Time-consuming Highly skill-dependent Suture trauma Poor alignment is common - even by experienced surgeons 40% of cadaver repairs are unacceptable1 1. Bernstein et al. JHS 2013; Isaacs et al. JHS 2016 Challenges with Suture- Based Nerve Repair 9 CONFIDENTIAL
Slide 11: NerveTape: First FDA-cleared Device for Sutureless Nerve Repair
Precisely align, connect, & protect transected nerves in a fraction of the time it would take to repair using conventional suture and conduit techniques Easily repair & connect transected nerves Eliminate the need for microsuture Nerve Tape is designed to: Eberlin KR, Safa B, Buntic RF, et al. Usabi
Slide 12: NerveTape vs. Microsuture
NerveTape vs. MicrosutureLink: 11 CONFIDENTIAL
Slide 13: Strategic Rationale
• Simpler, faster, more effective alternative to micro-suturing in nerve repair • Less dependency on microsurgical skills enables expansion and adoption of nerve repair to non-specialist surgeons and middle-adopters • Foundational technology base for future product development and indication expansi
Slide 14: Purchase Price and Key Financial Metrics
PURCHASE PRICE $ 2 0 0 M I L L I O N I N C A S H , S U B J E C T T O C U S T O M A R Y A D J U S T M E N T S KEY FINANCIAL METRICS • ~ $ 2 4 M M R U N - R A T E R E V E N U E Q 2 2 0 2 6 A N N U A L I Z E D ( $ 1 1 M M I N 2 0 2 5 ) • E X P E C T E D T O B E A C C R E T I V E T O R E V E N U E G R O
Slide 15: Our Investment Thesis is Reinforced by this Acquisition
Our Investment Thesis is Reinforced by this Acquisition Large Market Opportunity $5.6B TAM with minimal current penetration Clinical Leadership Unique and differentiated nerve repair portfolio backed by strong evidence Multiple Growth Catalysts Four distinct market development opportunities at diffe
Slide 16: Thank You
Thank You © 2026 Axogen Corporation. All rights reserved. The stylized "a" logo is a registered trademark of Axogen Corporation. CONFIDENTIAL